Neurochemical alterations in women with borderline personality disorder and comorbid attention-deficit hyperactivity disorder

World Journal of Biological Psychiatry

Volumn 11, Issue 2 PART 2, 2010, Pages 372-381

  Rüsch, Nicolas ^a,c   Boeker, Miriam ^a   Büchert, Martin ^a   Glauche, Volkmar ^a   Bohrmann, Carl ^a   Ebert, Dieter ^a   Lieb, Klaus ^b   Hennig, Jürgen ^a   Tebartz Van Elst, Ludger ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

^b JOHANNES GUTENBERG UNIVERSITY   (Germany)

^c ILLINOIS INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

Anterior cingulate; Borderline personality disorder; Glutamate; N acetylaspartate; Spectroscopy

Indexed keywords

CHOLINE; CREATINE; GLUTAMIC ACID; GLUTAMINE; INOSITOL; N ACETYLASPARTIC ACID;

ADULT; ARTICLE; ATTENTION DEFICIT DISORDER; BORDERLINE STATE; CEREBELLUM; CINGULATE GYRUS; CLINICAL ARTICLE; COMORBIDITY; CONTROLLED STUDY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; FEMALE; HUMAN; NEUROCHEMISTRY; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY;

ADULT; ASPARTIC ACID; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; BORDERLINE PERSONALITY DISORDER; BRAIN CHEMISTRY; CASE-CONTROL STUDIES; CEREBELLUM; CHOLINE; CREATINE; GLUTAMIC ACID; GLUTAMINE; GYRUS CINGULI; HUMANS; INOSITOL; MAGNETIC RESONANCE SPECTROSCOPY;

EID: 77950801481     PISSN: 15622975     EISSN: 18141412     Source Type: Journal    
DOI: 10.3109/15622970801958331     Document Type: Article

References (64)

1. Ashburner J, Friston KJ. 2005. Unified segmentation. Neuro Image 26:839-851.
2. Ashtari M, Kumra S, Bhaskar SL, Clarke T, Thaden E, Cervellione KL, et al. 2005. Attention-deficit/hyperactivity disorder: a preliminary diffusion tensor imaging study. Biol Psychiatry 57:448-455. (Pubitemid 40311978)
3. Beck AT, Steer RA. 1987. Beck-Depression-Inventory-Manual. San Antonio, TX: The Psychological Corporation.
4. Bernstein EM, Putnam FW. 1986. Development, reliability, and validity of a dissociation scale. J Nerv Ment Dis 174:727-735.
5. Bohus M, Limberger MF, Frank U, Sender I, Gratwohl T, Stieglitz RD. 2001. Entwicklung der Borderline-Symptom-Liste. Psychotherapie Psychosomatik Medizinische Psychologie 51:201-211.
6. Bohus M, Limberger M, Frank U, Chapman A, Kühler T, Stieglitz RD. 2007. Psychometric properties of the Borderline Symptom List. Psychopathology 40:126-132.
7. Bozkurt A, Zilles K, Schleicher A, Kamper L, Arigita ES, Uylings HB, et al. 2005. Distributions of transmitter receptors in the macaque cingulate cortex. NeuroImage 25:219-229.
8. Carrey N, MacMaster FP, Fogel J, Sparkes S, Waschbusch D, Sullivan S. 2003. Metabolite changes resulting from treatment in children with ADHD: a 1H-MRS study. Clin Neuropharmacol 26:218-221.
9. Castellanos FX, Lee PP, Sharp W, Jeffries NO, Greenstein DK, Clasen LS, et al. 2002. Developmental trajectories of brain volume abnormalities in children and adolescents with attention-deficit/hyperactivity disorder. J Am Med Assoc 288:1740- 1748.
10. Clark JB. 1998. N-Acetylaspartate: a marker for neuronal loss or mitochondrial dysfunction. Dev Neurosci 20:271-276.
11. Courvoisie H, Hooper SR, Fine C, Kwock L, Castillo M. 2004. Neurometabolic functioning and neuropsychological correlates in children with ADHD-H: preliminary findings. J Neuropsychiatry Clin Neurosci 16:63-69.
12. Davids E, Gastpar M. 2005. Attention deficit hyperactivity disorder and borderline personality disorder. Prog Neuropsychopharmacol Biol Psychiatry 29:865-877.
13. Davidson RJ, Putnam KM, Larson CL. 2000. Dysfunction in the neural circuitry of emotion regulation-a possible prelude to violence. Science 289:591-594.
14. de Graaf RA. 1998. In vivo NMR spectroscopy: Principles and techniques. Chichester: John Wiley & Sons.
15. Derogatis LR. 1977. SCL-90: Administration, Scoring, and Procedures Manual-I for the R(evised) version and other instruments of the psychopathology rating scale series. Baltimore, MD: John Hopkins University.
16. Fan J, McCandliss BD, Fossella J, Flombaum JI, Posner MI. 2005. The activation of attentional networks. NeuroImage 26:471-479.
17. Fayed N, Modrego PJ. 2005. Comparative study of cerebral white matter in autism and attention-deficit/hyperactivity disorder by means of magnetic resonance spectroscopy. Acad Radiol 12:566-569.
18. First MB, Gibbon M, Spitzer RL, Williams JBW, Benjamin LS. 1997. Structured Clinical Interview for DSM-IV Axis II Personality Disorders (SCID-II). Washington, DC: American Psychiatric Press.
19. Fossati A, Novella L, Donati D, Donini M, Maffei C. 2002. History of childhood attention deficit/hyperactivity disorder symptoms and borderline personality disorder: a controlled study. Comp Psychiatry 43:369-377.
20. Franke GH. 1992. Eine weitere Überprüfung der Symptom-Check-Liste (SCL-90-R) als Forschungsinstrument. Diagnostica 38:160-167.
21. Friedel RO. 2004. Dopamine dysfunction in borderline personality disorder: a hypothesis. Neuropsychopharmacology 29: 1029-1039.
22. Gallinat J, Kunz D, Lang UE, Neu P, Kassim N, Kienast T, et al. 2007. Association between cerebral glutamate and human behaviour: the sensation seeking personality trait. NeuroImage 34:671-678.
23. Govindaraju V, Young K, Maudsley AA. 2000. Proton NMR chemical shifts and coupling constants for brain metabolites. NMR Biomed 13:129-153.
24. Grosjean B, Tsai GE. 2007. NMDA neurotransmission as a critical mediator of borderline personality disorder. J Psychiatry Neurosci 32:103-115.
25. Halperin JM, Schulz KP. 2006. Revisiting the role of the prefrontal cortex in the pathophysiology of attention-deficit/ hyperactivity disorder. Psychol Bull 132:560-581.
26. Hazlett EA, New AS, Newmark R, Haznedar MM, Lo JN, Speiser LJ, et al. 2005. Reduced anterior and posterior cingulate gray matter in borderline personality disorder. Biol Psychiatry 58:614-623.
27. Herpertz SC, Zanarini M, Schulz CS, Siever L, Lieb K, Möller HJ, et al. 2007. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Personality Disorders. World J Biol Psychiatry 8:212-244.
28. Holcomb HH, Lahti AC, Medoff DR, Cullen T, Tamminga CA. 2005. Effects of noncompetitive NMDA receptor blockade on anterior cingulate cerebral blood flow in volunteers with schizophrenia. Neuropsychopharmacology 30:2275-2282.
29. Jang DP, Lee JM, Lee E, Park S, Kim JJ, Namkoong K, et al. 2005. Interindividual reproducibility of glutamate quantification using 1.5-T proton magnetic resonance spectroscopy. Magn Reson Med 53:708-712.
30. Lehrl S. 2005. Mehrfachwahl-Wortschatz-Intelligenztest MWT-B. 5th edition. Spitta, Balingen.
31. Lehrl S, Triebig G, Fischer B. 1995. Multiple choice vocabulary test MWT as a valid and short test to estimate premorbid intelligence. Acta Neurol Scand 91:335-345.
32. Lieb K, Zanarini MC, Schmahl C, Linehan MM, Bohus M. 2004. Borderline personality disorder. Lancet 364:453-461.
33. Lis E, Greenfield B, Henry M, Guile JM, Dougherty G. 2007. Neuroimaging and genetics of borderline personality disorder: a review. J Psychiatry Neurosci 32:162-173.
34. MacMaster FP, Carrey N, Sparkes S, Kusumakar V. 2003. Proton spectroscopy in medication-free pediatric attention-deficit/ hyperactivity disorder. Biol Psychiatry 53:184-187.
35. Moore CM, Biederman J, Wozniak J, Mick E, Aleardi M, Wardrop M, et al. 2006. Differences in brain chemistry in children and adolescents with attention deficit hyperactivity disorder with and without comorbid bipolar disorder: a proton magnetic resonance spectroscopy study. Am J Psychiatry 163: 316-318.
36. Murphy DG, Critchley HD, Schmitz N, McAlonan G, van Amelsvoort T, Robertson D, et al. 2002. Asperger syndrome: a proton magnetic resonance spectroscopy study of brain. Arch Gen Psychiatry 59:885-891.
37. Ni X, Chan K, Bulgin N, Sicard T, Bismil R, McMain S, et al. 2006. Association between serotonin transporter gene and borderline personality disorder. J Psychiatr Res 40:448-453.
38. Olbrich HM, Valerius G, Rüsch N, BüchertM, Thiel T, Hennig J, et al. 2008. Frontolimbic glutamate alterations in first episode schizophrenia: Evidence from a magnetic resonance spectroscopy study. World J Biol Psychiatry.
39. Paris J. 2005. The diagnosis of borderline personality disorder: problematic but better than the alternatives. Ann Clin Psychiatry 17:41-46.
40. Perlov E, Philipsen A, Hesslinger B, BüchertM, Ahrendts J, Feige B, et al. 2007. Reduced cingulate glutamate/glutamine-tocreatine ratios in adult patients with attention deficit/hyperactivity disorder-A magnet resonance spectroscopy study. J Psychiatr Res 41:934-941.
41. Pittenger C, Krystal JH, Coric V. 2005. Initial evidence of the beneficial effects of glutamate-modulating agents in the treatment of self-injurious behavior associated with borderline personality disorder. J Clin Psychiatry 66:1492-1493.
42. Posner MI, Rothbart MK, Vizueta N, Levy KN, Evans DE, Thomas KM, et al. 2002. Attentional mechanisms of borderline personality disorder. Proc Natl Acad Sci USA 99:16366- 16370.
43. Prost RW, Mark L, Mewissen M, Li SJ. 1997. Detection of glutamate/glutamine resonances by 1H magnetic resonance spectroscopy at 0.5 Tesla. Magn Reson Med 37:615-618.
44. Provencher SW. 1993. Estimation of metabolite concentrations from localized in vivo proton NMR spectra. Magn Reson Med 30:672-679.
45. Retz-Junginger P, Retz W, Blocher D, Weijers HG, Trott GE, Wender PH, et al. 2002.Wender Utah Rating Scale (WURS-k): Die deutsche Kurzform zur retrospektiven Erfassung des hyperkinetischen Syndroms bei Erwachsenen. Nervenarzt 73:830-838.
46. Ross B, Bluml S. 2001. Magnetic resonance spectroscopy of the human brain. Anat Rec 265:54-84.
47. Rothman DL, Behar KL, Hyder F, Shulman RG. 2003. In vivo NMR studies of the glutamate neurotransmitter flux and neuroenergetics: implications for brain function. Annu Rev Physiol 65:401-427.
48. Rüsch N, Tebartz van Elst L, Ludaescher P, Wilke M, Huppertz HJ, Thiel T, et al. 2003. A voxel-based morphometric MRI study in female patients with borderline personality disorder. NeuroImage 20:385-392.
49. Rüsch N, Luders E, Lieb K, Zahn R, Ebert D, Thompson PM, et al. 2007a. Corpus callosum abnormalities in women with borderline personality disorder and comorbid attention-deficit hyperactivity disorder. J Psychiatry Neurosci 32:417-422.
50. Rüsch N, Weber M, Il'yasov K, Lieb K, Ebert D, Hennig J, et al. 2007b. Inferior frontal white matter microstructure and patterns of psychopathology in women with borderline personality disorder and comorbid attention-deficit hyperactivity disorder. NeuroImage 35:738-747.
51. Scherk H, Backens M, Schneider-Axmann T, Usher J, Kemmer C, Reith W, et al. 2007. Cortical neurochemistry in euthymic patients with bipolar I disorder. World J Biol Psychiatry 1-10.
52. Schmahl C, Bohus M, Esposito F, Treede RD, Di Salle F, GreffrathW, et al. 2006. Neural correlates of antinociception in borderline personality disorder. Arch Gen Psychiatry 63:659- 667. (Pubitemid 43848297)
53. Schmahl C, Bremner JD. 2006. Neuroimaging in borderline personality disorder. J Psychiatr Res 40:419-427.
54. Schmahmann JD. 2004. Disorders of the cerebellum: ataxia, dysmetria of thought, and the cerebellar cognitive affective syndrome. J Neuropsychiatry Clin Neurosci 16:367-378.
55. Schneider M, Retz W, Coogan A, Thome J, Rosler M. 2006. Anatomical and functional brain imaging in adult attentiondeficit hyperactivity disorder-a neurological view. Eur Arch Psychiatry Clin Neurosci 256(Suppl 1):32-41.
56. Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, et al. 1998. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 59(Suppl 20):22-33.
57. Spitzer C, Freyberger HJ, Stieglitz RD, Carlson EB, Kuhn G, Magdeburg N, et al. 1998. Adaptation and psychometric properties of the German version of the Dissociative Experience Scale. J Trauma Stress 11:799-809.
58. Stone JM, Morrison P, Pilowsky LS. 2007. Glutamate and dopamine dysregulation in schizophrenia-a synthesis and selective review. J Psychopharmacol 21:440-452.
59. Tebartz van Elst L, Thiel T, Hesslinger B, Lieb K, Bohus M, Hennig J, et al. 2001. Subtle prefrontal neuropathology in a pilot magnetic resonance spectroscopy study in patients with borderline personality disorder. J Neuropsychiatry Clin Neurosci 13:511-514.
60. Tebartz van Elst L, Hesslinger B, Thiel T, Geiger E, Haegele K, Lemieux L, et al. 2003. Frontolimbic brain abnormalities in patients with borderline personality disorder: a volumetric magnetic resonance imaging study. Biol Psychiatry 54:163- 171.
61. Tebartz van Elst L, Ludaescher P, Thiel T, Büchert M, Hesslinger B, Bohus M, et al. 2007. Evidence of disturbed amygdalar energy metabolism in patients with borderline personality disorder. Neurosci Lett 417:36-41.
62. Theberge J, Al Semaan Y, Williamson PC, Menon RS, Neufeld RW, Rajakumar N, et al. 2003. Glutamate and glutamine in the anterior cingulate and thalamus of medicated patients with chronic schizophrenia and healthy comparison subjects measured with 4.0-T proton MRS. Am J Psychiatry 160:2231- 2233.
63. Todd RD, Botteron KN. 2001. Is attention-deficit/hyperactivity disorder an energy deficiency syndrome? Biol Psychiatry 50:151-158.
64. Ward MF, Wender PH, Reimherr FW. 1993. The Wender Utah Rating Scale: an aid in the retrospective diagnosis of childhood attention deficit hyperactivity disorder. Am J Psychiatry 150:885-890